Literature DB >> 7547687

Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice.

S Man1, M H Newberg, V L Crotzer, C J Luckey, N S Williams, Y Chen, E L Huczko, J P Ridge, V H Engelhard.   

Abstract

Previous results from this laboratory demonstrated that the dominant influenza A epitope recognized by HLA-A2.1-restricted cytotoxic T lymphocytes (CTL) from HLA-A2.1 transgenic mice was the matrix protein 1 (M1) peptide epitope that is immunodominant in human CTL responses. However, analysis of a large number of CTL lines revealed a subset of influenza A/PR/8/34-specific murine CTL that recognized an HLA-A2.1-restricted epitope distinct from M1. Using recombinant vaccinia viruses encoding different influenza gene segments, the epitope recognized by these CTL was shown to be derived from A/PR/8 non-structural protein 1 (NS1). Because these CTL did not recognize targets infected with the A/Alaska/6/77 strain of influenza, candidate peptide epitopes were synthesized based on sequences that included an HLA-A2.1-specific binding motif, and that differed between A/PR/8 and A/Alaska. All of these CTL recognized a nonamer and a decamer peptide which contained a common eight amino acid sequence and two distinct sets of binding motif residues. However, the nonamer peptide was able to sensitize CTL for half-maximal lysis at 80- to 2500-fold lower doses than either the octamer or decamer. The homologous peptide derived from A/Alaska NS1 contained conservative amino acid changes at positions 4 and 8, and was not recognized at any tested concentration, although it bound with higher affinity to HLA-A2.1 than the peptide from A/PR/8. The A/PR/8 NS1 nonamer epitope was also recognized by human influenza A-specific CTL derived from two individuals. These results substantiate the general utility of HLA class I transgenic mice for the identification of human CTL epitopes for other pathogens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547687     DOI: 10.1093/intimm/7.4.597

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  17 in total

1.  The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype.

Authors:  A C M Boon; G de Mutsert; Y M F Graus; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model.

Authors:  T Arichi; T Saito; M E Major; I M Belyakov; M Shirai; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design.

Authors:  Daniela Weiskopf; Lauren E Yauch; Michael A Angelo; Daisy V John; Jason A Greenbaum; John Sidney; Ravi V Kolla; Aruna D De Silva; Aravinda M de Silva; Howard Grey; Bjoern Peters; Sujan Shresta; Alessandro Sette
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

4.  Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.

Authors:  P Sarobe; C D Pendleton; T Akatsuka; D Lau; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

5.  Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes.

Authors:  E G M Berkhoff; E de Wit; M M Geelhoed-Mieras; A C M Boon; J Symons; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice.

Authors:  Michele P Marron; Robert T Graser; Harold D Chapman; David V Serreze
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-02       Impact factor: 11.205

7.  Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients.

Authors:  Masanori Terajima; John Cruz; Anita M Leporati; Laura Orphin; Jenny Aurielle B Babon; Mary Dawn T Co; Pamela Pazoles; Julie Jameson; Francis A Ennis
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

8.  CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice.

Authors:  Kyrie Felio; Hanh Nguyen; Christopher C Dascher; Hak-Jong Choi; Sha Li; Michael I Zimmer; Angela Colmone; D Branch Moody; Michael B Brenner; Chyung-Ru Wang
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

9.  Of mice and humans: how good are HLA transgenic mice as a model of human immune responses?

Authors:  Maya F Kotturi; Erika Assarsson; Bjoern Peters; Howard Grey; Carla Oseroff; Valerie Pasquetto; Alessandro Sette
Journal:  Immunome Res       Date:  2009-06-17

10.  A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.

Authors:  Maya F Kotturi; Jason Botten; John Sidney; Huynh-Hoa Bui; Lori Giancola; Matt Maybeno; Josie Babin; Carla Oseroff; Valerie Pasquetto; Jason A Greenbaum; Bjoern Peters; Joey Ting; Danh Do; Lo Vang; Jeff Alexander; Howard Grey; Michael J Buchmeier; Alessandro Sette
Journal:  PLoS Pathog       Date:  2009-12-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.